

REMARKS

Claim 1-35 remain pending in the application following entry of the amendments.

In the Restriction Requirement, the invention has been restricted to two inventive groups:


Group I: claims 1-16 and 34-35, drawn to a composition comprising a non-toxic lectin and a therapeutic agent, classified in classes 436 and 530, subclasses 827 and 396, for example; and

Group II: claims 17-33, drawn to a method for treating a neurological condition, classified in class 514 and subclasses 2 and 12 for example.

To reiterate the selection made in Applicants' July 17th, 2006 reply, Applicants elect Group I, claims 1-16 and 34-35, for initial examination without prejudice and expressly reserve the right to prosecute other non-elected claims at a later stage. With regard to specie election, Applicants hereby also elect SEQ ID NO: 1 (for Claim 3); a polypeptide (for Claim 4); a growth factor (for Claim 5), and a brain derived neurotrophic factor (BDNF) (for Claim 8), on which claims 1-16 and 34-35 read. This election is made without traverse.

Date: January 26, 2007

Respectfully submitted,


Ada O. Wong, Reg. No. 53,740
MORGAN, LEWIS & BOCKIUS LLP
2 Palo Alto Square
3000 El Camino Real, Suite 700
Palo Alto, California 94306
(650) 843-4000